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Somatostatin (SST), cortistatin (CORT), and its receptors (sst1–5), and ghrelin and its
receptors (GHS-R) are two highly interrelated neuropeptide systems with a broad range
of overlapping biological actions at central, cardiovascular, and immune levels among
others. Besides their potent regulatory role on GH release, its endocrine actions are high-
lighted by SST/CORT and ghrelin inﬂuence on insulin secretion, glucose homeostasis, and
insulin resistance. Interestingly, most components of these systems are expressed at the
endocrine pancreas and are actively involved in the modulation of pancreatic islet function
and, consequently inﬂuence glucose homeostasis. In addition, some of them also partic-
ipate in islet survival and regeneration. Furthermore, under severe metabolic condition as
well as in endocrine pathologies, their expression proﬁle is severely deregulated. These
ﬁndings suggest that SST/CORT and ghrelin systems could play a relevant role in pan-
creatic function under metabolic and endocrine pathologies. Accordingly, these systems
have been therapeutically targeted for the prevention or amelioration of certain metabolic
conditions (obesity) as well as for tumor growth inhibition and/or hormonal regulation in
endocrine pathologies (neuroendocrine tumors). This review focuses on the interrelation-
ship between SST/CORT and ghrelin systems and their role in severe metabolic conditions
and some endocrine disorders.
Keywords: SST, CORT, ghrelin, insulin, islet, pancreas, endocrine
INTRODUCTION
The pancreas is a physiologically and biologically complex organ
organized in exocrine and endocrine compartments which are
modulated by a wide variety of neuronal and hormonal signals in
an integrated manner. The exocrine function of the pancreas is
performed by more than 90% of the whole pancreatic tissue and
is essentially composed of acinar and ductal cells that respectively,
synthesize and transport enzymes crucial for nutrient digestion at
the gastrointestinal tract.
The endocrine function of the pancreas is in turn achieved
by distinct cell types organized in major structures called Islet of
Langerhans, which are scattered throughout the organ and are in
close contact with the vascular environment. At least ﬁve major
different endocrine cell types have been described: glucagon-
secreting alpha-cells, insulin-secreting beta-cells, somatostatin
(SST)-secreting delta-cells, ghrelin-producing epsilon-cells, and
pancreatic polypeptide-producing cells. The distribution and pro-
portion of endocrine cells within the pancreatic islets varies
between species (Jain and Lammert, 2009). The coordinated
production, release, action, and relationship of the above-
mentioned pancreatic endocrine peptides determine the constitu-
tive metabolic homeostasis within the organism. In this sense, the
endocrine dysfunction of the gland as the impairment of insulin
production triggers the development of type 2 diabetes mellitus
(T2DM) therefore, resulting in an abnormal regulation of blood
glucose concentration with ulterior signiﬁcant complications. It is
widely known the close relationship between type 2 diabetes and
obesity (Venables and Jeukendrup, 2009). In this sense, in fact,
obesity is a multi-factorial chronic metabolic condition that pre-
dispose to the development of T2DM and shares with the later
a common feature: insulin resistance (Saltiel and Kahn, 2001).
The increasing incidence of bothmetabolic disorders urges for the
search of therapeutic targets in order to treat these pathologies and
improve glucose homeostasis and insulin resistance, aswell as body
weight regulation. In this context, the action of the different ghre-
lin system components on glucose homeostasis, insulin resistance,
and body weight regulation has been described and consequently,
ghrelin system has been suggested as a potential drug target for
the prevention or treatment of T2DM and obesity. In turn, some
tissues are common targets of SST/cortistatin (CORT) and ghrelin
(i.e., endocrine pancreas) and interestingly, these three molecules
show a highlymolecular parallelism (i.e., all peptides are processed
from prepro-hormones that generate several biologically active
peptides). In the present review, we analyze the literature rela-
tive to the modulation of endocrine pancreatic function by these
two closely interrelated pleiotropic systems, SST/CORT, and ghre-
lin. Moreover, we also include its actions on glucose metabolism
and insulin release as well as their possible pathophysiological role
in metabolic disorders with increasing incidences as T2DM and
obesity.
SST/CORT PLEIOTROPIC SYSTEM
Somatostatin was originally isolated from ovine hypothalamus
based on its potent inhibitory action on pituitary growth hormone
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(GH) secretion (Brazeau et al., 1973). At circulation, it appears
in two biologically active forms consisting of 14 (SST-14) or 28
amino acid (aa) residues (SST-28), generated by differential post-
translational processing froma commonprecursormolecule. Both
isoforms are widely distributed in a number of organs and tis-
sues, although they display a particular tissue-speciﬁc expression
patterns. Thus, SST-14 is predominantly produced in the central
nervous system and in several peripheral tissues, including the
pancreas (Ballian et al., 2006), whereas SST-28 is mainly expressed
by epithelial cells of the gastrointestinal tract mucosa. Such wide
distribution of SST forms is consistent with its ever growing spec-
trum of biological and pathophysiological functions, mostly of
inhibitory nature, such as inhibition of endocrine and exocrine
secretions, neurotransmission, neuromodulation, gastrointesti-
nal motility, immune system function, tumor cell growth, and
pancreatic function (Patel, 1999).
A large amount of this wide biological capacity of SST is
mediated via binding and activation of SST receptors, a family
of ﬁve speciﬁc transmembrane proteins (named sst1–5) belong-
ing to the superfamily of G proteins coupled receptors (GPCRs),
and encoded by ﬁve distinct intronless genes (Gahete et al., 2010).
All ﬁve isoforms recruit several downstream transduction signals
upon SST binding such as adenylyl cyclase and calcium chan-
nels, which are two major players involved in SST inhibitory
action on hormone release. Similarly to SST tissue distribution,
ssts are present in abundant tissue locations and often, in SST
tissue targets, several isoforms are simultaneously present in the
same cell. In this context, it has been reported that ssts func-
tionally interact with each other and even with other GPCRs to
form homo- and/or heterodimers that activate different signal-
ing cascades and consequently mediate multiple biological actions
(Moller et al., 2003).
The pleiotropic activity featured by SST ﬁts well with both its
ample tissue distribution and its multiple receptors. Moreover, it
can also be likely related to the existence of a highly similar pep-
tide of the same family, CORT, which was originally discovered
in frogs and subsequently in rodents and humans (de Lecea et al.,
1996; Tostivint et al., 1996). Like SST, CORT is the product of an
enzymatically processed precursor, CORT prepro-peptide, which
shares high homology with SST precursor. SST and CORT pre-
cursors are encoded by two different genes that evolved from a
common ancestral gene by a duplication mechanism (Tostivint
et al., 1996; Gahete et al., 2010). Similar to that described for SST,
processing of CORT precursor generates diverse mature peptides
as CORT-14 and -29 in rodents and CORT-17 and -29 in humans.
In addition, CORT- and SST-mature forms shares 11 aas, which
include two cysteine residues responsible for their characteristic
cyclic structure and the FWKT core (Phe7-Trp8-Lys9-Thr10), a
crucial motif for receptor binding. Thus, their differences are
located at the N- and C-terminal regions. In sum, CORT and
SST sequence identity and structural homology explain well their
close pharmacology, speciﬁcally, their comparable subnanomolar
binding afﬁnity to the ﬁve sst isoforms.
Although CORT was initially discovered in the brain and it is
especially abundant in the cortex (where its name comes from),
further reports showed that this neuropeptide is also widely dis-
tributed at peripheral tissues including gastrointestinal tract and
pancreas. Based on its ability to activate ssts, CORT exhibits almost
endocrine and most non-endocrine actions of SST (Broglio et al.,
2008; Gahete et al., 2008). Actually, their main functional diver-
gences, reside in the ability of CORT to promote sleep functions,
modulate locomotor activity, exert potent anti-inﬂammatory
actions in experimentalmodels of inﬂammatory and autoimmune
disorders (de Lecea et al., 1996; Gonzalez-Rey and Delgado, 2008)
and, its inﬂuence on atherogenesis (Gonzalez-Rey and Delgado,
2008; Liu et al., 2010; Souza-Moreira et al., 2011).
Differential actions between SST and CORT possibly reside
in the ability of CORT to interact, in addition to ssts, with the
Mas-related gene 2 receptor (MrgX2), a former orphan receptor
originally suggested as speciﬁc for CORT. However, this recep-
tor appears to be a quite promiscuous GPCR that also shows some
speciﬁcity for proadrenomedullin and related peptides (Nothacker
et al., 2005). Interestingly, CORT is also able to bind ghrelin recep-
tor (GHS-R1a) by displacing its natural ligand from its binding
sites, capacity that is not shared by SST. In this sense, it has been
recently demonstrated that interaction of CORT with ghrelin sys-
tem precludes CORT to be a mere SST natural analog in the
regulation of endocrine secretions. Indeed, our laboratory have
recently demonstrated that CORT exhibits a stimulatory role on
prolactin (PRL) secretion in primates and mice, which could be
blocked in vitro by a GHS-R1a antagonist, a biological action that
is not elicited by SST (Cordoba-Chacon et al., 2011).
GHRELIN PLEIOTROPIC SYSTEM
The ghrelin gene, GHRL, encloses a 20-bp non-translated exon
(Ex0), four coding exons (Ex1–4) and three introns, being a
28-aa native ghrelin peptide the predominant product of the 117-
aa precursor pre-proghrelin (Kojima et al., 1999). Pre-proghrelin
includes the signal peptide encoded by Ex1, and the coding
sequence encoded by Ex2 and Ex3 which are the coding sequence
of ghrelin (Seim et al., 2007). This transcript processing also gen-
erates different peptides or variants such as obestatin (of 23 aas),
des-Glu14-ghrelin [matching to native ghrelin except for the dele-
tion of one aa (Glu in the position 14)], etc. (Kineman et al., 2007;
Seim et al., 2010).
Native ghrelin was originally isolated from the stomach of
humans and rats based on its potent GH releasing activity (Kojima
et al., 1999). Interestingly, native ghrelin has been the ﬁrst natu-
ral hormone to be identiﬁed in which its third residue, usually
a serine in mammals, contains the addition of a middle-chain
fatty acid (n-octanoic acid) crucial for its biological activity.
This post-translational modiﬁcation is catalyzed by the ghrelin
O-acyltransferase (GOAT; Gutierrez et al., 2008; Yang et al., 2008),
a membrane bound O-acyltransferase located at the endoplas-
mic reticulum that uses fatty acids from the diet to fulﬁll its
action (Kojima and Kangawa, 2005). Afterward, either acylated-
or unacylated-proghrelin can be further processed by the prohor-
mone convertase 1/3 (PC1/3) thus generating the acylated-ghrelin
or its unacylated-ghrelin counterpart, a form of ghrelin initially
considered as inactive (Zhu et al., 2006). Surprisingly, circulat-
ing unacylated-ghrelin levels are signiﬁcantly higher than those of
acylated-ghrelin in a proportion that depends on the study con-
sidered (Hosoda et al., 2000; Yoshimoto et al., 2002; Broglio et al.,
2004; Liu et al., 2008).
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Acylated-ghrelin elicits its biological actions through the GH-
secretagogue receptor type-1a, GHS-R1a, previously known as
an orphan receptor that mediates the GH-releasing effect of syn-
thetic GH secretagogues, a group of peptide and non-peptide
compounds with GH releasing properties. Currently, GHS-R1a is
also called the ghrelin receptor based on the description of ghrelin
as its natural ligand (Kojima et al., 1999).
The GHS-R gene consist of two exons whose transcription
and processing originate two distinct forms of cDNAs: GHS-R1a,
encoded by both exons, and a shorter form, GHS-R1b, derived
from the exclusive transcription of the ﬁrst exon (Howard et al.,
1996; Kojima and Kangawa, 2005). The full-length of human
GHS-R1a is a highly conserved protein of 366 aas that belong to
the GPCR family containing seven putative membrane spanning
alpha-helical segments and three intracellular and extracellular
loops (Howard et al., 1996). GHS-R1a speciﬁcally recognizes the
binding of acylated-ghrelin but not that of unacylated-ghrelin,
whose speciﬁc receptor remains to be identiﬁed. In contrast, GHS-
R1b isoform is an alternatively truncated variant of 289 aas that
only possesses the ﬁrst ﬁve transmembrane domains of GHS-1a
(Howard et al., 1996; Kojima and Kangawa, 2005), and it was con-
sidered, until recently, to be a non-functional GHS-R isoform
based on its inability to bind acylated-ghrelin. Interestingly, it has
been recently described the interaction of GHS-R1b with GHS-
R1a and other receptors to form heterodimers (Muccioli et al.,
2007), as well as the heterodimerization of GHS-R1a with SST
and dopamine receptors (Seim et al., 2010).
In terms of signal transduction, it has been described that
GHS-R1a activation involves the participation of several signal-
ing cascades including phospholipase C (PLC), protein kinase C
(PKC), protein kinase A (Kojima and Kangawa, 2005) intracellu-
lar and extracellular Ca2+, and mitogen-activated protein kinases
(Mousseaux et al., 2006; Camina et al., 2007).
Different components of the ghrelin system have been found to
be ubiquitously represented in the organism. Speciﬁcally, ghre-
lin was originally described to be predominantly produced by
endocrine cells of the stomach submucosa (Kojima et al., 1999). In
addition, it was also documented to be produced at other portions
of the gastrointestinal tract from the stomach to the colon and
in a wide variety of peripheral tissues like the pancreas (Kojima
et al., 1999; Date et al., 2000). It has also been showed the expres-
sion of ghrelin at different locations of the central nervous system
(Ueberberg et al., 2009). The wider ghrelin tissue distribution is
mimicked by that of GOAT,particularly inmajor ghrelin-secreting
tissues (Gutierrez et al., 2008; Yang et al., 2008; Sakata et al., 2009)
although GOAT transcripts appear to be much lower expressed
than ghrelin transcripts. However, it has been documented that
a small proportion of ghrelin expressing cells devoid of GOAT
expression thus suggesting and supporting that unacylated-ghrelin
might show independent biological actions to that described for
ghrelin (Jeffery et al., 2011) and most probably by distinct recep-
tor and mechanisms to those recruited by ghrelin (Toshinai et al.,
2006; Sato et al., 2012).
On the other hand, GHS-R1a expression has been also widely
detected in tissues or organs including pancreas, liver, stom-
ach, adipose tissue, small and large intestine, immune system,
and others (Gnanapavan et al., 2002; Sun et al., 2007; Ueberberg
et al., 2009). In strikingly contrast, expression of GHS-R1b has
been described to be even more extensive than that of GHS-R1a
(Gnanapavan et al., 2002).
According to the wide tissue distribution of the different ghre-
lin system components, many physiological actions have been
documented for this system. Based on the high conservation
degree among species of ghrelin and its receptor sequences, it
has been suggested that ghrelin system plays essential biological
actions. In fact, and as mentioned earlier, acylated-ghrelin was
initially identiﬁed based on its ability to stimulate GH release
upon GHS-R1a coupling in a similar manner to that described
for GH secretagogues (Kojima et al., 1999). Also involving GHS-
R1a activation, ghrelin elicits an orexigenic role by promoting food
intake or appetite (Wren et al., 2000; Druce et al., 2005, 2006) and
weight gain and adiposity (Tschop et al., 2000; Wren et al., 2000,
2001). Ghrelin has also shown regulatory properties on glucose
and energy homeostasis that will be revised separately. In addi-
tion to its metabolic actions, ghrelin has also been reported to
exert potent anti-inﬂammatory actions in therapeutically relevant
models of arthritis or inﬂammatory bowel disease (Gonzalez-Rey
et al., 2006; Gonzalez-Rey and Delgado, 2008) and also inﬂu-
ence atherogenesis (Kadoglou et al., 2012). Furthermore, ghrelin
shows favorable effects on cardiovascular and gastroenteropan-
creatic physiology (Isgaard and Granata, 2011), as well as on the
modulation of the immune system (Souza-Moreira et al., 2011). At
the central nervous system, ghrelin inﬂuences memory, learning,
and behavior functions (Asakawa et al., 2001; Broglio et al., 2003).
Besides the above-described stimulatory effect on GH release,
pituitary function is also regulates by ghrelin by stimulating the
release of PRL and adrenocorticotropin (van der Lely et al., 2004;
Coiro et al., 2005).
On the other hand, unacylated-ghrelin, plays both equal or
opposite biological actions to that above described for acyl-ghrelin,
most probably through its coupling to a still unknown receptor
different from GHS-R1a, as it has been recently suggested and
documented (Toshinai et al., 2006; Lear et al., 2010; Togliatto et al.,
2010).Moreover, regulation of unacylated-ghrelin secretion under
food restriction conditionhas been reported, thus supporting anot
passive role for this unmodiﬁed peptide (Kirchner et al., 2009).
Regarding obestatin, this 23-aa peptide is mainly produced in
the stomach and at lower level in the pancreas, spleen, testis, duo-
denum, jejunum, colon, and mammary gland (Ren et al., 2009).
To date, although obestatin receptor remains unknown, it has
been proposed that GPR39 or glucagon-like peptide-1 receptor
might be potential receptors for obestatin (Granata et al., 2008;
Ren et al., 2009).
ACTIONS OF SST/CORT SYSTEM AT THE
ENDOCRINE PANCREAS
Somatostatin has long been known to potently modulate pancre-
atic function by playing a regulatory role on insulin and glucagon
secretion. This tight regulation is accomplished by the coordinated
action of SST biologically active forms. In this sense, SST-14 is the
major product released by adult pancreatic delta-cells, whose con-
tribution to total circulating SST accounts for nearly 5%. SST-14
immediate actions imply the paracrine regulation of other pancre-
atic endocrine cells. In addition, endocrine pancreatic function is
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also under the control of the major circulating SST form, SST-28.
In this context, it has been documented that SST-14 and SST-
28 differently target pancreatic alpha- or beta-cells. Accordingly,
SST-14 has been associated with the inhibition of glucagon secre-
tion while SST-28 seems preferentially to inhibit insulin secretion
(Strowski and Blake, 2008). In either case, inhibitory action of
SST on both insulin and glucagon release would contribute to
preserve glucose homeostasis which, in turn, retrospectively reg-
ulates SST plasma concentration. For this reason, during fasting,
plasma SST level is low and increases up to twofold after meals.
In such hyperglycemic conditions, insulin induces SST release and
consequently shuts down its own release as a protective mecha-
nism to prevent a rapid hypoglycemia at the post-prandial state.
In contrast, SST release is also increased at lowplasma glucose con-
centration as a consequence of the coordinated action of glucagon
and L-glutamate, a co-secretion product of alpha-cells (Strowski
and Blake, 2008).
The SST actiononpancreatic hormones ismediated by its inter-
action with the different receptor isoforms, however, conﬂicting
data about receptor expression at the pancreatic level have been
published which, might be related with the different method used
and/or species analyzed. In general, it is likely that endocrine pan-
creas expresses all ﬁve sst isoforms, being probably sst1, sst2, and
sst5 those expressed in a predominant manner. Speciﬁcally, it has
been demonstrated by RT-PCR that rodent pancreas expresses all
sst isoforms except sst4. In turn, by double immunohistochem-
istry methods, it has been conﬁrmed the expression of sst2 and
sst5 in both rodent beta- and delta-cells. In humans, it has been
reported a predominant expression of sst2 in alpha-cells, sst1 and
sst5 in beta-cells, and sst5 in delta-cells while there is not consis-
tent data on the expression of the rest of ssts (Strowski and Blake,
2008; Gahete et al., 2010).
In addition, and in order to ascertain the subtype receptors
underlying the inhibitory effect of SST on pancreatic hormones,
speciﬁc receptor agonists, and antagonists as well as knock out
mouse models with deletion of the different ssts isoforms have
been employed. These issues have been amply revised elsewhere
(Strowski and Blake, 2008) and brieﬂy, it appears that sst2 seems
to mediate glucagon inhibition and sst5 looks as the main recep-
tor mediating insulin inhibition in rodents. More recently, high
expression of sst3 has been also demonstrated in mouse pancre-
atic islets (Regard et al., 2008). In human, by contrast, sst2 looks
to be the main receptor mediating both insulin and glucagon
release, although sst1 and sst5 also participate in the regulation
of insulin secretion (Gahete et al., 2010). In summary, several sst
isoforms would mediate the inhibitory action of SST on insulin
and glucagon secretion through a mechanism that indubitably is
species-dependent, and will essentially depend on the receptor
expression pattern.
In relation to CORT and its role on pancreatic function, only
a few studies are available. Particularly and similarly to SST,
CORT expression has been reported at the endocrine pancreas
and essentially mimics its inhibitory action on insulin secretion
under physiological and certain pathological conditions (Grottoli
et al., 2006; Broglio et al., 2008), although the molecular mecha-
nism underlying such inhibitory action is still unclear. In addition,
it should be highlighted that CORT is also able to elicit distinct
functions to that showed by SST mainly through its coupling to
the ghrelin receptor (GHS-R1), as it has been recently documented
for others endocrine secretions (Cordoba-Chacon et al., 2011).
ACTIONS OF GHRELIN SYSTEM AT THE
ENDOCRINE PANCREAS
After ghrelin discovery, it was reported that pancreatic epsilon-
cells are the major source of ghrelin forms during fetal life until
early post-natal period (Wierup et al., 2002; Chanoine and Wong,
2004). After this period, the major source of ghrelin production is
the stomach submucosa (Kojima et al., 1999) while, the pancreas
turns on a secondary source of ghrelin production with low level
of ghrelin receptor expression (Veldhuis and Bowers, 2010). At
the pancreas, the major source of ghrelin resides into epsilon-cells
(Wierup et al., 2002, 2004; Prado et al., 2004) although it appears
that is also produced by beta-cells in humans (Volante et al., 2002)
and by glucagon-producing alpha-cells in human and rats (Date
et al., 2002). In any case and in terms of ghrelin production, it
has been described that during adult life the 65–90% of circulat-
ing ghrelin corresponds to that synthesized and released by the
stomach, being the rest derived from other tissues including the
pancreas and the intestine (Al Massadi et al., 2011).
Endocrine ghrelin actions at the pancreas involve inhibition of
SST release by delta-cells, and stimulation of glucagon release by
alpha-cells (Qader et al., 2005, 2008; Veldhuis and Bowers, 2010;
Chuang et al., 2011) as well as inhibition of pancreatic polypeptide
release by PP cells (Qader et al., 2008; Kumar et al., 2010), being
all cells types in which GHS-R expression has been documented
(Wierup et al., 2002, 2004; Kageyama et al., 2005; Dezaki et al.,
2008; Granata et al., 2010a). On the other hand, SST and glucagon
have also been shown to elicit a reciprocal modulation of ghrelin
production (Figure 2). Furthermore, it has been reported that
insulin and SST inhibit ghrelin release while glucagon inhibits its
secretion in rodent although stimulate ghrelin release in humans
(Qader et al., 2008).
Although ghrelin effect on insulin secretion is supported by
an increasing number of reports, its precise role is nevertheless
controversial since either stimulatory or inhibitory actions has
been reported depending on the ghrelin doses used and/or experi-
mental conditions employed as recently reviewed by Granata et al.
(2010a,b). Speciﬁcally, the ghrelin stimulatory effect of insulin
release is mainly mediated by an increase of cytosolic Ca2+ upon
GHS-R activation, while the participation of a different recep-
tor has been proposed based on the observed stimulatory action
of both acylated- and unacylated-ghrelin on insulin release in
a hamster beta-cell line devoid of GHS-R expression (Granata
et al., 2007). In addition, it has also been described that ghrelin
administration increases insulin release in rats under conditions
of low blood insulin as a consequence of a 90% pancreatec-
tomy (Kerem et al., 2009). Reciprocally, insulin inhibits ghrelin
expression (Veldhuis and Bowers, 2010) and more recently it
has been proposed that insulin might act as an inhibitor of
pancreatic ghrelin activation by inhibition of GOAT expression
(An et al., 2011).
In clear contrast to the above stimulatory role of ghrelin on
insulin secretion, the ghrelin inhibitory actionhas beenprevalently
reported and examined in several biological and animal models
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including cultured pancreata, cultured islets and heterologous cell
models (Granata et al., 2010a; Dezaki et al., 2011), as well as by
using several methodological approaches. Overall, it has been
described that ghrelin administration signiﬁcantly reduces insulin
secretion (Broglio et al., 2001; Tong et al., 2010), and this action
was blocked in the presence of a higher dose of unacylated-ghrelin,
suggesting the participation of a receptor distinct to GHS-R on
insulin secretion modulation (Qader et al., 2008). Reduction of
insulin level by ghrelin administration triggers a concomitant ele-
vation of blood glucose levels in a dose-dependent manner as
well as deterioration of insulin sensitivity during glucose toler-
ance, as it have been described in both humans and rodents
(Korbonits and Grossman, 2004; Dezaki et al., 2008; Tong et al.,
2010; Sato et al., 2012). The hyperglycemic action of ghrelin,
but not by unacylated-ghrelin in rodents, was blocked by simul-
taneous administration of GHS-R antagonist thus revealing the
speciﬁc participation of GHS-R in the hyperglycemic role of ghre-
lin (Dezaki et al., 2008). In addition, GHS-R deletion also reduces
blood glucose level and signiﬁcantly enhances insulin sensitivity
(Longo et al., 2008; Qi et al., 2011). Importantly, the involvement
of GH (a long time known hyperglycemic hormone) has been
excluded from the hyperglycemic effect of ghrelin administration
based on elevated plasma glucose levels observed in response to
exogenous ghrelin administration in GH-deﬁcient mice (Dezaki
et al., 2008) and subjects with GH-deﬁciency (Vestergaard et al.,
2008). Similarly, ghrelin hyperglycemic effect have been reported
to be independent of an insulin resistance induction as evidenced
by insulin and glucose tolerance tests after ghrelin administration
(Dezaki et al., 2008).
In order to ascertain whether the insulinostatic action of ghre-
lin is due to the peptide derived from the stomach or other sources
as the pancreas, GHS-R antagonist was administered to gastrec-
tomized animals and a signiﬁcant increase in insulin secretion
was observed in a similar extend to that observed in normal rats.
This observation suggests that intra-islet ghrelin may locally act
on insulin production regulation (Dezaki et al., 2007). However,
Bando et al. (2012) recently reported that intra-islet ghrelin does
not play a major local role on the regulation of insulin release
in vivo, based on their ﬁndings on transgenic mice in which ghre-
lin and GOAT were overexpressed in beta-cells. The discrepancy
between these two later studies may reside on the different ghrelin
concentration reached at the surrounding microenvironment of
beta-cells.
In addition to the regulatory role of ghrelin on pancreatic
function, it has also been described that acylated- and unacylated-
ghrelin as well as obestatin elicit a protective role by preventing
apoptosis on pancreatic islet in rodents, humans, and sev-
eral beta-cell lines (Granata et al., 2012b). In this sense, it has
been reported that beta-cell destruction elicited by streptozo-
tocin administration was precluded by ghrelin by increasing both
beta-cell mass and insulin release in rats (Irako et al., 2006). Fur-
thermore, ghrelin and obestatin also protect against apoptosis
induced by serum starvation and cytokines in both human islets
and beta-cell lines (Granata et al., 2007, 2008, 2010a). In well
agreement with this, ghrelin and obestatin exert their mitogenic
effect by increasing the number of beta-cells in 90% pancrea-
tectomized rats (Kerem et al., 2009) and in a hamster beta-cells
line (Granata et al., 2010a), proliferative action that was blocked
by administration of ghrelin antagonist or ghrelin antibody
(Kerem et al., 2009; Granata et al., 2010a). These ﬁndings sug-
gest that a cross-talk between ghrelin and obestatin may exist
(Granata et al., 2008).
ROLE OF SST/CORT SYSTEM IN T2DM AND OBESITY
They are not many reports on the role of SST/CORT in situations
with altered metabolic conditions. In this sense, an increase in
the number of SST-producing cells in T2DM patients has been
recently described, although circulating SST remains in the same
level to that depicted by control subjects. However, in an exper-
imental model of obese and spontaneously diabetic mice, SST
content is signiﬁcantly increased (Strowski and Blake, 2008). In
this scenario, the well established inhibitory actions of SST on
pancreatic function, particularly on insulin and glucagon secre-
tion (Figure 1) as well as its inhibitory action on intestinal glucose
absorption, predicted its use as a key tool to potentially regu-
late glucose homeostasis and insulin sensitivity in diabetes and
obesity (Hansen et al., 2004; Tzotzas et al., 2008). Indeed, initial
studies evaluated SST role on insulin hypersecretion as well as
in hyperinsulinemia associated with obesity, two conditions that
were described to induce insulin resistance (Janson and Oberg,
1999; Boehm, 2003). Consequently, signiﬁcant reductions in body
weight and insulin release as well as an improvement of insulin
sensitivity were observed in obese patients treated with synthetic
SST analogs (Boehm and Lustig, 2002; Velasquez-Mieyer et al.,
2004; Lustig et al., 2006; Tzotzas et al., 2008), which were originally
developed as a consequence of the SST short half-life. Similarly to
SST, it has also been reported an inhibitory action of CORT on
insulin release in patients with acromegaly or prolactinoma (Grot-
toli et al., 2005). In relation to CORT, and based on its described
anti-inﬂammatory properties, it would be of interest to explore
its role on the inﬂammatory signaling that occurs during obesity
conditions.
FIGURE 1 | Diagram of SST actions on islet cell release. Arrow heads
represent SST from extrapancreatic origins (mostly intestinal).
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FIGURE 2 | Diagram of ghrelin actions on islet cell release. Arrow heads
represent ghrelin from extrapancreatic origins (mostly stomach). “>>>”
denotes that the majority of published studies describe an inhibitory effect
of ghrelin on insulin release.
More recently, the effect of a multi-ligand SST analog
(pasireotide) on hormones that mediate glucose homeostasis has
been described in healthy volunteers (Golor et al., 2012; Shenouda
et al., 2012). Accordingly, based on the high binding afﬁnity for
four of the ﬁve SST receptor subtypes (sst1–3, and sst5) elicited
by pasireotide, it has been administered to healthy subjects and
an elevation of blood glucose has been observed mainly as a con-
sequence of its inhibitory action on both insulin and glucagon
release (Shenouda et al., 2012). Similar hyperglycemic effect of
pasireotide has been observed in clinical trials in which pasireotide
administration was evaluated on patients with endocrine patholo-
gies as Cushing’s disease, acromegaly, and neuroendocrine tumors
(NETs). In these pathologies, hyperglycemia might be further
worsened in base to their inherent hormonal nature (Boscaro
et al., 2009; Petersenn et al., 2010; Colao et al., 2012). Furthermore,
variable sst1–5 expression has been extensively documented and
consequently SST analogs have been classically used after adenoma
or tumor resection. Lastly, SST analogs have been used as a ﬁrst
option therapy in selected patients upon its ability to reduce hor-
monal release and/or to inhibit tumor mass progression. In these
cases, alterations in glucose homeostasis aswell as impaired insulin
resistance has been well documented as a secondary effect to their
characteristic underlying hormonal secretion (Resmini et al., 2009;
Shenouda et al., 2012).
In different series of acromegalic patients, a signiﬁcant preva-
lence of impaired glucose metabolism and diabetes mellitus has
been described, a consequence that is believed to be originated
by the excess GH (van der Hoek et al., 2005; Espinosa-de-los-
Monteros et al., 2011; Fieffe et al., 2011; Kinoshita et al., 2011). In
such GH hypersecreting conditions, the universal sst binding pro-
ﬁle of pasireotide and its higher efﬁcacy by lowering GH release
more signiﬁcantly than sst2 preferential or speciﬁc SST analogs
(octreotide and lanreotide) granted its therapeutical use. However,
as mentioned above in these subjects, the risk of hyperglycemia
increases as a common adverse event originated by the normal-
ization of GH and IGF-1 levels as well as the inhibition of insulin
release by SST administration (Resmini et al., 2009).
Somatostatin analogs have also been applied in the manage-
ment of NET suffering patients in which, similarly to acromegalic
individuals, an altered glucose tolerance has been documented
(Cirillo, 2010). Such altered glucose tolerance may occur as a
consequence of hormonal dysregulation or pancreatic resection
(Resmini et al., 2009; Jawiarczyk et al., 2012).
Hypercortisolism condition, a distinctive characteristic of
Cushing’s disease, also leads to hyperglycemia and reduced glu-
cose tolerance and as a result, in an increase of the prevalence
of diabetes in this pathology (Mazziotti et al., 2009, 2011; Resmini
et al., 2009). Furthermore, hyperglycemia persists evenwhen corti-
sol level declines by administration of SST analogs, i.e., pasireotide
as it has been recently reported (Colao et al., 2012).
In sum, hyperglycemia conditions occur in an elevated pro-
portion of individuals suffering of acromegaly, Cushing’s disease
or NET and accordingly, it has been proposed that regular blood
glucose testing and insulin analogs will be required, particularly
when SST analogs are therapeutically used in these pathologies
(Resmini et al., 2009; Colao et al., 2012).
ROLE OF GHRELIN SYSTEM IN T2DM AND OBESITY
As mentioned earlier, a growing body of studies supports the
inhibitory role of ghrelin on insulin release in vivo and in vitro and
its inﬂuence on glucose tolerance. Accordingly, it has been pro-
posed that the antagonism of ghrelin system components could
improve glucose homeostasis and/or beta-cell function under cer-
tain metabolic disorders as T2DM, a complex disease with a
strong genetic, behavioral, and environmental background that
is characterized by two distinctively conditions: insulin resis-
tance and progressive beta-cell dysfunction. In T2DM, beta-cells
become unable to adequately increase insulin release to compen-
sate insulin resistance and consequently leading to a situation of
hyperglycemia. It is well known the close association between
T2DMandobesity in terms ofmetabolic imbalance and their com-
mon features, insulin resistance, in which ghrelin system could
be of relevance based on its ability to modulate both glucose
homeostasis and weight loss (Esler et al., 2007).
Under normal metabolic conditions, circulating ghrelin and
plasma glucose concentrations are inversely related. In fact, ghre-
lin levels are increased under fasting conditions or immediately
before meals and signiﬁcantly decreased after feeding (Angelidis
et al., 2010). Obviously, the meal-related pattern of ghrelin is also
opposite to that depicted by insulin and consequently the fall of
ghrelin at post-prandial state has been argued to partially depend
on the rise of insulin release after food intake (Solomon et al.,
2008). Accordingly, the tight relationship between ghrelin and
insulin also relies in the general assumption that insulin elicits a
negative action on both plasma acylated- and unacylated-ghrelin
concentration (Saad et al., 2002; McLaughlin et al., 2004), while
administration of acylated-ghrelin results in insulin resistance
(Gauna and van der Lely, 2005).
In subjects affected by T2DM and consequently resistant to
insulin, it has been showed that blood ghrelin concentration was
chronically lower than that observed in healthy subjects evenwhen
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age, sex, and body mass index (BMI) were adjusted, probably
as a direct effect of insulin on ghrelin-producing cells (Poykko
et al., 2003; Angelidis et al., 2010; Verhulst and Depoortere, 2012).
Based on the inﬂuence of ghrelin on insulin release and glu-
cose homeostasis, it has been suggested that ghrelin antagonism
could be of interest to treat T2DM and related metabolic patholo-
gies. In this context, it has been shown that deletion of ghrelin
gene promotes insulin release and ameliorates glucose intoler-
ance and hyperglycemia in a diabetic and obese mice model (Sun
et al., 2006). In well agreement with this, GHS-R ablation also
improves insulin sensitivity (Gomez et al., 2009). Likewise, it has
also been documented an improvement of glucose homeosta-
sis in streptozotocin-induced diabetic rats treated with obestatin
(Granata et al., 2010b) as well as a reduction in insulin resistance
in mice fed with a high fat diet (Granata et al., 2012a).
On the other hand, obesity conditions have been associated
with some ghrelin and GHS-R gene variations although some dis-
crepancies exist depending on studies and population considered
(Pantel et al., 2006; Liu et al., 2007; Ukkola, 2011). In this sense,
available data are still inconclusive and might be limited by some
relatively small analyzed cohorts that might restrict the power of
association.
However, it has been well documented that under obesity con-
ditions plasma ghrelin levels negatively correlate with BMI and
consequently with factors or parameters that are elevated in obe-
sity such as insulin, leptin, and fat mass (Tschop et al., 2001). In
this sense a chronic lower ghrelin plasma concentration in obese
children and adults has been reported in comparison with those of
age-matched lean controls (Tschop et al., 2001; Reinehr et al., 2008;
Schellekens et al., 2010). Similar data have been cited for Pima
Indians, a population reported with the highest prevalence rates of
obesity andT2DMwhen comparedwithCaucasians (Tschop et al.,
2001). Similarly to that reported under normal metabolic condi-
tion, ghrelin also elicits a meal-related pattern although under
obesity conditions the fall of ghrelin level at post-prandial state is
less pronounced. Such downregulation might be a consequence
of elevated fasting insulin or leptin levels observed in obesity
(Baragli et al., 2011). In this sense, it has also been suggested
that the decreased secretion of ghrelin, could be responsible for
the concomitant decreased levels of circulating GH observed in
obese individuals (Maccario et al., 2000; Tschop et al., 2001). More
recently, the decreased ghrelin concentration observed in obesity
could be an adaptive mechanism to maintain energy homeostasis
has also been proposed (Tschop et al., 2001). In rodents, dimin-
ished ghrelin levels have been found at tissue level as well as a
signiﬁcant reduction in plasma ghrelin concentration and synthe-
sis in obesity conditions induced by diet (Sahin et al., 2011; Aydin
et al., 2012).
Targeting ghrelin system components by different pharma-
cological, immunological, and genetic approaches have been
addressed in order to promote weight loss and to improve obesity
conditions (i.e., insulin resistance). Thus, some studies evaluated
pharmacological approaches to block or neutralize either ghrelin
or its receptor under diet-induced obesity and how these meth-
ods ameliorate obesity condition by reducing appetite or food
intake, and ultimately inducing weight loss (Wortley et al., 2005;
Schellekens et al., 2010; Briggs and Andrews, 2011). Another set of
studies, examined the protection of ghrelin system against rapid
weight gain by exposure to a high fat diet by knocking out either
ghrelin (Wortley et al., 2005) or GHS-R (Castaneda et al., 2010). In
these studies, an improvement of glucose tolerance was observed
even though there is no effect on body weight (Zigman et al., 2005;
Longo et al., 2008). Similar data were obtained in a genetically
obese mice model (ob/ob; leptin deﬁcient) in which the improve-
ment of insulin sensitivity and glucose homeostasis was attributed
to ghrelin although the obese phenotype remains unchanged (Sun
et al., 2006).
In addition, it has also been proposed that GOAT by a spe-
ciﬁc inhibitor could be a potential treatment against obesity by
inhibiting ghrelin acylation and consequently avoid weight gain
(Gualillo et al., 2008; Yang et al., 2008; Gomez et al., 2009; Barnett
et al., 2010).
On the other hand, diet-induced weight loss elicits an increase
in circulating ghrelin levels thus normalizing them until near opti-
mal concentration, rise that probably may hamper the sustained
weight loss (Cummings et al., 2002; Hansen et al., 2002). In cases
of morbid obesity, a more drastic method as bariatric surgery
has been employed in order to reduce metabolic complications
associated to obesity. Interestingly and contrary to that reported
in diet-induced weight loss, after bariatric surgery ghrelin level
signiﬁcantly decreases and insulin sensitivity is rapidly restored,
thus improving the associated diabetic state (Beckman et al., 2010;
Hillman et al., 2011). In this context, sustained low ghrelin level
reached by this surgical procedure precludes or delays weight gain
by reducing hunger, an effect that is not observed in procedures as
weight loss by diet modiﬁcation in which ghrelin levels gradually
normalizes with a consequent weight gain. On the other hand,
in morbid obese patients, it has been suggested that equimolar
administration of acylated- and unacylated-ghrelin also improve
insulin sensitivity (Kiewiet et al., 2009).
Unfortunately, there is not yet a ghrelin system based therapy
that ensures a sustained weight loss, although ghrelin antago-
nist and/or GOAT inhibitors may be considerate good therapeutic
candidates for the treatment of T2DM and obesity.
CONCLUSION
The complex relationship of ligand–receptor architecture of
SST/CORT and ghrelin systems is complemented by the func-
tional relevance of their common tissue targets. Indeed, besides
their opposite inﬂuence on GH release at the pituitary level,
SST/CORT and ghrelin systems act on the same cellular tar-
get to inﬂuence common and relevant biological actions as it is
the case of their interactions on beta cell function and survival
as well as on glucose homeostasis and insulin resistance. How-
ever, the underlying molecular mechanisms of these actions have
not been fully elucidated yet. Interestingly, different and severe
metabolic dysfunctions as T2DM and obesity have been described
to modulate their circulating levels and the expression of some
components of both systems at hypothalamic, pituitary, or pan-
creatic level. In sum, there are an increasing number of evidences
that support a potential contribution of SST/CORT and ghre-
lin system components in the endocrine pancreas dysfunction
in prevalent neuroendocrine-metabolic pathologies (T2DM and
obesity) which suggest that these systems could be considered as
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future valuable therapeutic targets for the prevention or treatment
of such metabolic disorders. In this sense, future research will be
of particular importance in order to ascertain whether SST/CORT
and ghrelin systems and its receptors will act at pancreatic islets
under physiological and pathological conditions. Likewise, the
underlying molecular mechanisms as well as the precise role
and the contribution of islet derived-SST, -CORT, and -ghrelin
in the pancreatic endocrine deregulation and/or the resulting
insulin resistance under severe metabolic conditions should be
investigated.
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